Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 3
1999 pubmed 30 citations

Growth hormone and hexarelin prevent endothelial vasodilator dysfunction in aortic rings of the hypophysectomized rat.

Rossoni. G G; Locatelli. V V; De Gennaro Colonna. V V; Torsello. A A; Schweiger. F F; Boghen. M M; Nilsson. M M; Bernareggi. M M; Müller. E E EE; Berti. F F

Key Findings

  • Hypophysectomy reduces endothelial release of 6‑keto‑PGF1α and impairs acetylcholine‑induced relaxation
  • Growth hormone and hexarelin both reverse the heightened response to endothelin‑1 and restore normal vasodilation
  • Hexarelin improves vascular function without increasing IGF‑I or body weight, implying a direct endothelial receptor effect

Practical Outcomes

  • Hexarelin may have vascular‑protective properties independent of growth‑hormone pathways, which could interest longevity enthusiasts. However, because the data are from a rat model with high injectable doses, there’s no established human dosing or safety profile. Until human studies emerge, it’s not ready for a DIY protocol, but it highlights a potential avenue for future research.

Summary

In rats without a pituitary gland, both growth hormone and the peptide hexarelin fixed problems with blood vessel lining that normally help vessels relax. Hexarelin did this without raising growth‑factor levels or causing weight gain, hinting it works directly on the vessel cells. The study suggests hexarelin could protect blood vessels, but it’s an animal experiment and hasn’t been tested in people yet.

Abstract

The endothelial vasodilation mechanism(s) has been investigated in aortic rings of hypophysectomized male rats as well as hypophysectomized rats treated for 7 days with growth hormone (GH, 400 microg/kg, s.c.) or hexarelin (80 microg/kg, s.c.). Tissue preparations from intact animals were taken as controls. The results obtained indicate that the release of 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha) from aortic rings of hypophysectomized rats was markedly reduced (51%; p<0.01) as compared with that of control preparations; the peak response to cumulative concentration of endothelin-1 (ET-1, from 10(-11) to 10(-5) M) was increased 2.4-fold (p<0.01) versus controls; the relaxant activity of acetylcholine (ACh, from 10(-10) to 10(-4) M) in norepinephrine-precontracted aortic rings was reduced by 39.5+/-4.4%. Pretreatment of hypophysectomized rats with GH or hexarelin markedly antagonized the hyperresponsiveness of the aortic tissue to ET-1 and allowed a consistent recovery of both the relaxant activity of ACh and the generation of 6-keto-PGF1alpha. Collectively these findings support the concept that dysfunction of vascular endothelial cells may be induced by a defective GH function. Because a replacement regimen of GH restored the somatotropic function and increased plasma insulin-like growth factor-I (IGF-I) concentrations in the hypophysectomized rats, it is suggested that IGF-I may have protected the vascular endothelium acting as a biologic mediator of GH action. In contrast to GH, hexarelin replacement neither increased body weight nor affected the plasma concentrations of IGF-I, indicating that its beneficial action on vascular endothelium was divorced from that on somatotropic function and was likely due to activation of specific endothelial receptors.

Study Information

Provider

pubmed

Year

1999

Date

1999-09-01T00:00:00.000Z

DOI

10.1097/00005344-199909000-00021

Citations

30

References

21